Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486036 | 0.93 | HTR6 (0.53) | HTR6DRD3CYP2C9 | |
| SCHEMBL4475547 | 0.86 | HTR6 (0.69) | HTR6DRD3CYP2C9ALDH1A1LMNA | |
| SCHEMBL4483071 | 0.82 | HTR6 (0.66) | HTR6DRD3 | |
| SCHEMBL5095065 | 0.74 | HTR6 (0.52) | HTR6NPC1 | |
| Hydrochloric Acid SCHEMBL34475197 | 0.73 | CYP2C9 (0.59) | HTR6DRD3CYP2C9 | |
| SCHEMBL5091052 | 0.72 | PKM (0.43) | HTR6DRD3RIPK2NOD2NPC1 | |
| SCHEMBL4488601 | 0.72 | HTR6 (0.74) | HTR6ALDH1A1 | |
| SCHEMBL18553718 | 0.72 | KDM4E (0.65) | HTR6KDM4EALDH1A1LMNA | |
| SCHEMBL5103838 | 0.72 | KHK (0.45) | HTR6RIPK2NOD2NPC1 | |
| SCHEMBL5095090 | 0.71 | HTR6 (0.55) | HTR6RIPK2NOD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | claimed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | claimed |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| EP-1506179-B1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2006-01-25 | — | — | EP | disclosed |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | BERGER JACOB (US) | 2005-06-16 | — | — | US | disclosed |
| US-6867204-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1506179-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003095434-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | F12, CYP4X1, CYP3A5 | HTR6 2321/4885DRD3 1529/4885CYP2C9 13/4885 |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | F12, HAX1, CYP4X1 | HTR6 2220/4885DRD3 1476/4885CYP2C9 15/4885 |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | CYP3A5, CYP4X1, XDH | HTR6 1363/4885DRD3 1172/4885CYP2C9 14/4885 |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F12, CYP4X1, CYP3A5 | HTR6 2321/4885DRD3 1529/4885CYP2C9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.